87 results on '"Scagliotti G"'
Search Results
2. EP08.01-060 Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data
3. EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity
4. P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study
5. P50.05 Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study
6. MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center
7. PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
8. 581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1
9. 580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity
10. 1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer
11. O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
12. O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
13. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
14. P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era
15. O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer
16. OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer
17. YI01.02 Why to Become a Member of the IASLC
18. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
19. The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
20. OA07.07 Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018
21. P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma
22. MA21.03 The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer
23. Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018
24. SP-0209 Multidisciplinary approaches as the keys to defeat lung cancer
25. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
26. P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma
27. PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial
28. 213O Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study
29. MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool
30. P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma
31. P2.09-003 Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment
32. MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study
33. OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma
34. PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma
35. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
36. LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)
37. 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ)
38. 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ)
39. Pharmacological bioquivalence of branded and generic oxaliplatin: from preclinical assessment to clinical incidence of hypersensitivity reactions in patients with colorectal cancer
40. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
41. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
42. Symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid
43. The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations
44. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients
45. 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials
46. Phospho-mTOR expression levels, proliferative acitivity (Ki67) and pancreatic primary tumor may influence the response to everolimus in neuroendocrine tumor patients: results from an Italian preliminary study
47. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
48. Two Phase III Studies Evaluating Ceritinib in Patients (Pts) with Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): Ascend-4 and Ascend-5
49. A Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for 1St Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer (Nsclc): the Elderly Patient Individualized Chemotherapy (Epic) Trial
50. An Exploratory Phase 2 Study of Pemetrexed (Pem) and Cisplatin (Cis) As Preoperative Chemotherapy (Ct) in the Treatment of Stage Iiian2 Nonsquamous Non-Small Cell Lung Cancer (Ns Nsclc)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.